Lu177 ‐PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution

ConclusionOur study reported an 18 ‐month overall survival of 64% in patients with mCRPC who have undergone LuPSMA therapy. Our study identified that baseline serum PSA, SUVmax and biochemical response to treatment are prognostic markers for increased overall survival.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Medical Imaging —Radiation Oncology—Original Article Source Type: research